<DOC>
	<DOC>NCT02595203</DOC>
	<brief_summary>The primary objectives of this study are: - To determine the mass balance recovery (expired air, urine and faeces) and route and rate of elimination of 14C-Debio 1450. - To determine the metabolic profile of 14C-Debio 1450 in whole blood, plasma, urine and faeces. - To determine the pharmacokinetics of total radioactivity and of Debio 1450 (prodrug) and Debio 1452 (active moiety) in plasma and urine.</brief_summary>
	<brief_title>Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Meets protocolspecified criteria for qualification and contraception Is willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related to food, drink and medications Voluntarily consents to participate and provides written informed consent prior to any protocolspecific procedures Has history or current use of overthecounter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocolspecified parameters Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1. the safety or wellbeing of the participant or study staff 2. the safety or wellbeing of the participant's offspring (such as through pregnancy or breastfeeding) 3. the analysis of results</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Bioavailability</keyword>
</DOC>